93 209

Cited 5 times in

Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study

DC FieldValueLanguage
dc.contributor.author천근아-
dc.contributor.author최솔-
dc.contributor.author송동호-
dc.contributor.author신의진-
dc.date.accessioned2014-12-19T17:37:24Z-
dc.date.available2014-12-19T17:37:24Z-
dc.date.issued2012-
dc.identifier.issn1738-3684-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/91757-
dc.description.abstractOBJECTIVE: This study was aimed to determine effectiveness and tolerability of Osmotic-controlled Release Oral delivery (OROS) methylphenidate (MPH) and its optimal dose administered openly over a period of up to 12 weeks in drug naïve Korean children with ADHD. METHODS: Subjects (n=143), ages 6 to 18-years, with a clinical diagnosis of any subtype of ADHD were recruited from 7 medical centers in Korea. An individualized dose of OROS-MPH was determined for each subject depending on the response criteria. The subjects were assessed with several symptom rating scales in week 1, 3, 6, 9 and 12. RESULTS: 77 of 116 subjects (66.4%) achieved the criteria for response and the average of optimal daily dose for response was to 30.05±12.52 mg per day (0.90±0.31 mg/kg/d) at the end of the study. Optimal dose was not significantly different between ADHD subtypes, whereas, significant higher dose was needed in older aged groups than younger groups. The average of optimal daily dose for response for the subjects aged above 12 years old was 46.38±15.52 per day (0.81±0.28 mg/kg/d) compared to younger groups (p<0.01). No serious adverse effects were reported and the dose did not have a significant effect on adverse effects. CONCLUSION: Optimal mean dose of OROS-MPH was significantly different by age groups. Higher dose was needed in older aged groups than younger groups. Effectiveness and tolerability of OROS-MPH in symptoms of ADHD is sustained for up to 12 weeks.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfPsychiatry Investigation-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleTitrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Psychiatry (정신과학)-
dc.contributor.googleauthorDong-Ho Song-
dc.contributor.googleauthorSoul Choi-
dc.contributor.googleauthorYoo Sook Joung-
dc.contributor.googleauthorEun Hye Ha-
dc.contributor.googleauthorBoong-Nyun Kim-
dc.contributor.googleauthorYee-Jin Shin-
dc.contributor.googleauthorDongwon Shin-
dc.contributor.googleauthorHee Jeong Yoo-
dc.contributor.googleauthorKeun-Ah Cheon-
dc.identifier.doi10.4306/pi.2012.9.3.257-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA04027-
dc.contributor.localIdA04090-
dc.contributor.localIdA02018-
dc.contributor.localIdA02136-
dc.relation.journalcodeJ02569-
dc.contributor.alternativeNameCheon, Keun Ah-
dc.contributor.alternativeNameChoi, Soul-
dc.contributor.alternativeNameSong, Dong Ho-
dc.contributor.alternativeNameShin, Yee Jin-
dc.contributor.affiliatedAuthorCheon, Keun Ah-
dc.contributor.affiliatedAuthorChoi, Soul-
dc.contributor.affiliatedAuthorSong, Dong Ho-
dc.contributor.affiliatedAuthorShin, Yee Jin-
dc.citation.volume9-
dc.citation.number3-
dc.citation.startPage257-
dc.citation.endPage262-
dc.identifier.bibliographicCitationPsychiatry Investigation, Vol.9(3) : 257-262, 2012-
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실)

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.